The European Investment Bank (EIB) is the biggest multilateral financial institution in the world and one of the largest providers of finance for climate action, providing economic support to sectors that contribute significantly to technological innovation,  growth, employment, regional cohesion and environmental sustainability in Europe and beyond. The EIB loan was provided to Fresenius in 2021 based on the expenditures in Research, Development and Innovation (RDI) in its portfolio of biosimilars, generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. The RDI activities in scope focus on developing lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Based on the outcomes of the materiality assessment 2023, we consider following topical standards of the European Sustainability Reporting Standards as material:

• Climate change
• Pollution
• Water and marine resources
• Resource use and circular economy
• Own workforce
• Workers in the value chain
• Consumers and end-users
• Digitalization
• Innovation
• Business conduct
• Cybersecurity

Our materiality analysis is based on the principle of double materiality and complies with the requirements of the European Sustainability Reporting Standards. The aim is to identify the material impacts, risks, and opportunities that arise in our own business and along our value chain. The sustainability aspects that are relevant for us and our stakeholders arise from this. 

In line with the principle of double materiality, we have considered sustainability from two different perspectives:

• Impact materiality: includes all potential and actual positive and negative impacts of Fresenius’ operations on our stakeholders, including social and environmental impacts
• Financial materiality: includes all financial risks and opportunities that could affect Fresenius’ future profitability due to sustainability aspects. This encompasses the financial performance, results of operations, cash flows, access to finance or cost of capital of Fresenius.

A sustainability aspect fulfills the double materiality criterion if it is material from either or both perspectives.  

 

Stakeholders and partnerships

Fresenius is integrated into a diverse network of interest groups. From this exchange, we gain valuable insights that help us to continuously improve the management of material topics and reporting.

We engage with our stakeholders through a variety of channels. The corporate functions at Fresenius primarily focus on stakeholders who are relevant to the Group as a whole. The business segments actively engage with patients, employees, customers, and regulatory authorities, among others. 

For the integration of affected stakeholders in our operating activities, we consider, for example findings from existing due diligence processes and risk assessments in the area of quality, internal employee satisfaction surveys, dialogs with employee representatives and works councils, patient and customer surveys. Another important element of our stakeholder dialogs is our active participation in industry and interest groups, as well as our exchange with business partners.

 

 

For more information on this topic see the Sustainability Statement.

 

Our contribution to the UN Sustainable Development Goals

The 17 Sustainable Development Goals (SDGs) with 169 targets, adopted by the 191 member states of the United Nations (UN) back in 2015, are the roadmap for tackling mankind´s key challenges on the path to a more sustainable world, such as poverty, discrimination and climate change. To achieve these goals, the public sector, governments and companies must work together.  

As a global healthcare group, we are doing our part. Our activities might be relevant with regards to all the 17 SDGs, we see a direct link between our core business activities and our sustainability ambition and the SDGs listed below.  

For a holistic overview of our sustainability related activities incl. potential risks, please refer to our Sustainability Statement and our Sustainability Highlights Magazine 2024. 

(Last updated on December 2017)

We have compiled our website very carefully and it is continually expanded and updated. Nevertheless, we assume no liability for the accuracy or completeness of the contents. We do not assume any liability for direct, indirect, material or immaterial damages that may arise from the use of the information provided on this website, except when incorrect information is published intentionally or with gross negligence. Subject to the foregoing, the use of the website is at the user’s own personal risk.

For US users: Some jurisdictions may not permit certain disclaimers of warranties, so some of the exclusions above may not apply to you. In such jurisdictions, we disclaim warranties to the fullest extent permitted by applicable law.

Business information and product information

The information on this website is non-binding and intended for general information purposes only. It is not a substitute for professional financial, medical or other specialist advice. Users should not act upon this information without first seeking appropriate professional advice. Further, we are not responsible for the content of third party texts published on this website. The individual authors are responsible for their works. We do not assume any liability for damages, which arise from the use of this information.

Releases on this website may contain forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in these releases.

Rights of use

Fresenius or its affiliates are owners of all proprietor rights attaching to the web page prepared. All texts and illustrations are covered by copyright. You may take note of the information in our websites and load them into your main memory. The use of press releases as well as documents, pictures and video footage available in the media center shall be permitted solely for editorial reporting purposes. Any further reproduction or passing on to third parties shall be excluded. No rights or licenses of any kind with respect to trademarks, copyrights, patents, etc. shall be granted to the user.

Non-commitment - applicable law

It is possible that the promotion for or the procurement of individual products, services and therapies portrayed on this website is not permissible under the legal regulations valid in individual countries outside of the European Union. The web page shall not constitute a promotion of these products, services and therapies for these countries. Please note that the products displayed on this website may not be available in all countries due to different registration status. Our local subsidiaries’ websites may include different legal provisions and your use of such websites shall be subject to the provisions provided therein.
Any legal claims or lawsuits that may arise in conjunction with this website or its use are subject to the interpretation of the laws of the Federal Republic of Germany, excluding the provisions of international private law and the UN Convention on Contracts for the International Sale of Goods.

Hyperlinks

We also offer links to third-party websites in addition to our own information. The content and design of third-party websites are beyond our control. We do not ensure that the information on third-party websites is accurate or correct. The links also represent no endorsement, support or confirmation of the contents at the linked sites. The individual authors of the linked sites are responsible for the information, opinions and facts presented on their web pages. The same is true for comments made in guest books, discussion forms and e-mail lists. We are likewise not responsible for the technical security of both the links and target pages. We are therefore not liable for any damages that occur through use of either the information contained on these hyperlinks or the use of the hyperlinks themselves.

Contact and further information

© 2000 - 2017 Fresenius SE & Co. KGaA

Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172 608 0
Fax: +49 (0) 6172 608 2294
E-mail: pr-fre@fresenius.com

Published by:

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register Bad Homburg, HRB 11852
Supervisory Board: Wolfgang Kirsch (Chairman)

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch

Value Added Tax Identification Number (VAT ID): DE 114152311

Edited by:

Fresenius SE & Co. KGaA
Corporate Communications
61346 Bad Homburg v.d.H.
Germany
pr-fre@fresenius.com

Programming:

Fresenius Digital Technology GmbH
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H

 
This imprint is also valid for the Social Media platforms of Fresenius.

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

RSS feeds keep you up to speed on the latest developments within the Fresenius Group. Always in real time and directly on your computer or mobile device.

Fresenius offers you two different RSS feeds:

 

RSS feed Investor News

RSS feed Press Releases

 

Furthermore, you can find additional RSS feeds with job openings on our career website.

 

You can read RSS feeds using an RSS-enabled Web browser. Alternatively, there are special programs called feed readers.

 

For more information on RSS, please consult i. e. Wikipedia.